Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 1:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neoplasms of Prostate Clear all
Terminated Phase 1 Interventional

Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy

NCT03619655
View directory record Official record
Conditions
Prostate Cancer
Interventions
SPECT CT, 18F-DCFPyL PET/CT, 18F-NaF PET/CT, WB-MRI
Procedure · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Sep 22, 2026, 1:58 AM EDT
Active, not recruiting Phase 2 Interventional

Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy

NCT04915508
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Hormone Therapy, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Completed No phase listed Observational

An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings

NCT05362149
View directory record Official record
Conditions
Non-metastatic Castration-resistant Prostate Cancer
Interventions
Darolutamide (Nubeqa, BAY1841788), Enzalutamide, Apalutamide
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 22, 2026, 1:58 AM EDT
Terminated Phase 1Phase 2 Interventional

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

NCT06257758
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Breast Cancer, Recurrent Ovarian Cancer, Prostate Cancer
Interventions
VIO-01
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Lake Mary, Florida • Oklahoma City, Oklahoma • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer

NCT00499408
View directory record Official record
Conditions
Prostate Cancer
Interventions
Vitamin D, soy
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 2Phase 3 Interventional

Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer

NCT00004071
View directory record Official record
Conditions
Prostate Cancer
Interventions
leflunomide, mitoxantrone hydrochloride, prednisone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
3
States / cities
Boca Raton, Florida • Fort Myers, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

NCT01046916
View directory record Official record
Conditions
Prostate Cancer
Interventions
TAK-700
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Ann Arbor, Michigan • Portland, Oregon • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Not applicable Interventional

Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer

NCT02470897
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma
Interventions
Radiation Therapy Treatment Planning and Simulation, SBRT
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Male only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
3
States / cities
Rockford, Illinois • Johnson Creek, Wisconsin • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 22, 2026, 1:58 AM EDT
Withdrawn Not applicable Interventional

Proton Therapy for High Risk Prostate Cancer

NCT01811810
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation therapy (XRT), Androgen Deprivation Therapy (ADT), Chemotherapy
Radiation · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 1 Interventional

A Study of PRT2527 in Participants With Advanced Solid Tumors

NCT05159518
View directory record Official record
Conditions
Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer, Solid Tumors With Known MYC Amplification
Interventions
PRT2527
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Denver, Colorado • Celebration, Florida • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

NCT01322490
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
PROSTVAC-V, PROSTVAC-F, GM-CSF, GM-CSF Placebo, Placebo
Biological · Drug · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
84
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Berkeley, California + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 22, 2026, 1:58 AM EDT
Recruiting No phase listed Observational

Outcomes of Focal Ablation for Prostate Cancer

NCT05478694
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Recruiting Phase 2 Interventional

Radiation Therapy Approaches for People With Prostate Cancer

NCT07751159
View directory record Official record
Conditions
Prostate Cancer Patients, Non-metastatic Prostate Cancer, High Risk Prostate Cancer
Interventions
Standard of Care HDR Brachytherapy, SBRT
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer

NCT00072670
View directory record Official record
Conditions
Prostate Cancer
Interventions
Trabectedin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Sep 22, 2026, 1:58 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

NCT07336446
View directory record Official record
Conditions
Prostate Cancer
Interventions
AZD9750, AZD5305
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Duarte, California • San Francisco, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Recruiting Phase 1 Interventional

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

NCT04890613
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
CX-5461
Drug
Lead sponsor
Senhwa Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Santa Monica, California • Tampa, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Terminated Not applicable Interventional Results available

A Pilot Study of the Feasibility of Chronic Cavernous Nerve Stimulation to Promote Regeneration and Erectile Function

NCT02006927
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nerve Stimulation
Device
Lead sponsor
Kenneth M Peters, MD
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 22, 2026, 1:58 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00527124
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage IV Prostate Cancer
Interventions
cediranib maleate, docetaxel, prednisone, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
Detroit, Michigan • Houston, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Not applicable Interventional

A Study of Grape Seed Extract in Asymptomatic Non-Metastatic Prostate Cancer Patients With Rising PSA

NCT03087903
View directory record Official record
Conditions
Prostate Cancer
Interventions
Grape Seed Extract
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 22, 2026, 1:58 AM EDT
Terminated Phase 1 Interventional

Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer

NCT04421222
View directory record Official record
Conditions
Prostate Cancer
Interventions
EPI-7386 (QD), EPI-7386 (BID), Abiraterone acetate, Apalutamide
Drug
Lead sponsor
ESSA Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Port Saint Lucie, Florida • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 22, 2026, 1:58 AM EDT
Recruiting No phase listed Observational

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

NCT04075305
View directory record Official record
Conditions
Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer, Brain Tumor, Brain Cancer, Gynecologic Tumor, Prostate Tumor, Prostate Neoplasm, Breast Tumor, Radiation Toxicity, Quality of Life, Rectal Cancer, Rectal Tumor, Rectal Neoplasms, Lung Cancer, Lung Tumor, Lung Neoplasm, Esophageal Cancer, Esophagus Cancer, Esophageal Tumor, Esophageal Neoplasm, Esophagus Tumor, Esophagus Neoplasm, Pancreatic Cancer, Pancreatic Tumor, Pancreatic Neoplasms, Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Tumor, Tumor, Neoplasms, Bladder Cancer, Bladder Neoplasm, Liver Cancer, Liver Neoplasms, Liver Metastases, Oligometastases
Interventions
Radiation therapy
Radiation
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Houston, Texas • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance

NCT05852041
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8
Interventions
Biopsy of Prostate, Decipher Prostate Cancer Test, Flotufolastat F-18 Gallium, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Radical Prostatectomy
Procedure · Genetic · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2035
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 22, 2026, 1:58 AM EDT
Active, not recruiting Phase 2 Interventional

Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

NCT02807805
View directory record Official record
Conditions
Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Abiraterone Acetate, Niclosamide, Prednisone
Drug
Lead sponsor
Mamta Parikh
Other
Eligibility
19 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 22, 2026, 1:58 AM EDT
Completed Not applicable Interventional

RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)

NCT05176756
View directory record Official record
Conditions
Cardiovascular Diseases, Breast Cancer, Prostate Cancer, Physical Inactivity
Interventions
Gamification and Social Support, Attention control
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Duarte, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Sep 22, 2026, 1:58 AM EDT